Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder.
Saved in:
| Title: | Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder. |
|---|---|
| Authors: | Fu DJ; Clinical Development, Janssen Scientific Affairs, 1125 Trenton-Harbourton Rd, Titusville, NJ 08560 dfu@its.jnj.com., Turkoz I, Simonson RB, Walling DP, Schooler NR, Lindenmayer JP, Canuso CM, Alphs L |
| Source: | The Journal of clinical psychiatry [J Clin Psychiatry] 2015 Mar; Vol. 76 (3), pp. 253-62. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Physicians Postgraduate Press Country of Publication: United States NLM ID: 7801243 Publication Model: Print Cited Medium: Internet ISSN: 1555-2101 (Electronic) Linking ISSN: 01606689 NLM ISO Abbreviation: J Clin Psychiatry Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
